CN111227243A - Food with special medical application formula - Google Patents
Food with special medical application formula Download PDFInfo
- Publication number
- CN111227243A CN111227243A CN202010129786.2A CN202010129786A CN111227243A CN 111227243 A CN111227243 A CN 111227243A CN 202010129786 A CN202010129786 A CN 202010129786A CN 111227243 A CN111227243 A CN 111227243A
- Authority
- CN
- China
- Prior art keywords
- autophagy
- food
- hmb
- special medical
- sarcopenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 62
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 29
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 29
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 24
- 230000004900 autophagic degradation Effects 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108010082399 Autophagy-Related Proteins Proteins 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 5
- 101150011918 ATG13 gene Proteins 0.000 claims description 6
- 101150102163 ATG7 gene Proteins 0.000 claims description 6
- 102000004072 Beclin-1 Human genes 0.000 claims description 6
- 108090000524 Beclin-1 Proteins 0.000 claims description 6
- 101100190557 Caenorhabditis elegans vps-34 gene Proteins 0.000 claims description 6
- 101150096483 atg5 gene Proteins 0.000 claims description 6
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 claims description 5
- 102000016956 Autophagy-Related Protein-1 Homolog Human genes 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000002222 downregulating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 40
- 210000003205 muscle Anatomy 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 102100020814 Sequestosome-1 Human genes 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010016173 Fall Diseases 0.000 description 1
- 208000003899 Foreign-Body Granuloma Diseases 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010038536 Renal tubular atrophy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- -1 UlK1 Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention specifically relates to a formula food with special medical application, which comprises β -hydroxy- β -methylbutyric acid as an active ingredient and has a treatment effect on chronic renal failure sarcopenia, wherein β -hydroxy- β -methylbutyric acid regulates and controls the expression reversal of autophagy-related genes and autophagy key proteins to treat the chronic renal failure sarcopenia.
Description
Technical Field
The invention relates to the field of health-care food, in particular to food with a special medical application formula.
Background
Chronic renal insufficiency is a common and serious disease that endangers human health. With the worsening of Renal function, accumulation of metabolites, reduction of dietary intake, micro-inflammation, insulin resistance and the like, patients with Chronic Renal Failure are very likely to suffer from muscle mass reduction, muscle strength reduction, selective muscle structure change and obvious muscle atrophy, which is called Chronic Renal Failure Sarcopenia (CRF-S). The chronic renal failure sarcopenia is manifested by hypodynamia, difficulty in walking, falling down and even fracture, and meanwhile, the chronic renal failure sarcopenia can also increase cardiovascular complications, hospitalization rate, all-cause mortality and social and family economic burden of patients. However, it is easy to ignore because of its long course of disease and lack of specific expression. Therefore, improvement of chronic renal failure sarcopenia is a clinical problem to be solved.
The muscle mass of the aged with chronic obstructive pulmonary disease is reduced by 1.5g/d HMB, wherein the muscle mass of the aged with chronic obstructive pulmonary disease is reduced by 0.81kg, 0.77kg, 0.82kg and 0.65 kg respectively after 30 days, 60 days and 90 days, and the muscle mass of the aged with chronic obstructive pulmonary disease is reduced by more than 2.6g after oral administration, wherein the muscle mass of the aged with chronic obstructive pulmonary disease is reduced by more than 2.5 g/d HMB after 24 weeks, and the aged with chronic obstructive pulmonary disease is reduced by more than 2.6g after oral administration.
Disclosure of Invention
In order to solve the above problems, the present invention aims to provide a food with a formulation for specific medical use for the treatment of sarcopenia with chronic renal failure.
In order to achieve the purpose, the technical scheme of the invention is that the food with a formula for special medical purposes comprises β -hydroxy- β -methylbutyric acid as an active ingredient.
Furthermore, the formula food for special medical application has a treatment effect on chronic renal failure sarcopenia.
Furthermore, the β -hydroxy- β -methylbutyric acid regulates the expression of autophagy-related genes and autophagy key proteins and treats sarcopenia caused by chronic renal failure.
Further, the autophagy-related genes are LC3B, Beclin1, ULK1, Atg5, Atg7, Atg13 and vps-34.
Further, the β -hydroxy- β -methylbutyric acid can be used for reducing the expression of the autophagy related gene.
Further, the autophagy key protein is LC3B and p 62.
Further, the β -hydroxy- β -methylbutyric acid regulates the down-regulation of the expression of an autophagy key protein LC3B and the up-regulation of the expression of p 62.
Compared with the prior art, the invention has the beneficial effects that:
(1) β -hydroxy- β -methylbutyric acid (HMB) can effectively improve sarcopenia caused by chronic renal failure, and the weight, muscle mass and muscle cross-sectional area of a rat are increased by regulating autophagy key genes and proteins, so that the sarcopenia of the rat with the chronic renal failure is improved.
(2) The project is based on the research on the aspects of pathogenesis and intervention treatment of the common chronic renal failure sarcopenia which does not cause enough attention, provides a new thought and a new treatment target point for clinically treating the disease, and has good popularization and application prospects.
Detailed Description
The technical solution of the present invention will be further described with reference to the following specific examples.
As shown in figures 1-6, a food for special medical purposes, the active ingredient of the food for special medical purposes is β -hydroxy- β -methylbutyric acid.
Furthermore, the formula food for special medical application has a treatment effect on chronic renal failure sarcopenia.
Further, the β -hydroxy- β -methylbutyric acid regulates the expression of autophagy-related genes and autophagy key proteins to treat sarcopenia caused by chronic renal failure.
Further, the autophagy-related genes are LC3B, Beclin1, ULK1, Atg5, Atg7, Atg13 and vps-34.
Further, the β -hydroxy- β -methylbutyric acid is used for reducing the expression of the autophagy related gene.
Further, the autophagy key protein is LC3B and p 62.
Further, the β -hydroxy- β -methylbutyric acid regulates the down-regulation of the expression of an autophagy key protein LC3B and the up-regulation of the expression of p 62.
Experimental example: male SD rats 6-8 weeks old and weighing about 250-300 g were divided into model, control and HMB treated groups according to a randomized basis, each group consisting of 6 rats. Model group: administering 250mg/kg/d adenine continuously for 14 days, and then changing to alternate daily administration (adenine dose and concentration are unchanged) until 28 days; control group: infusing the stomach with normal saline with the same volume and frequency as those of the adenine for 28 days; HMB treatment group: the administration is carried out for 35 days from 7 days before the start of the adenine intragastric administration to the end of the adenine intragastric administration, and the administration is carried out for 320mg/kg/d HMB. Detecting the weight of each group of rats, right tibialis anterior muscle (wet weight, dry weight/weight and cross-sectional area), related blood indexes and pathological sections of kidney and gastrocnemius to confirm the success of model building of chronic renal failure sarcopenia rats and the treatment effect of HMB; the rat gastrocnemius autophagy key gene and protein are detected to prove that HMB improves chronic renal failure sarcopenia by regulating autophagy.
From the second week of the experiment, the weight, the wet weight, the dry weight/the weight and the cross-sectional area of the right tibialis anterior muscle of the model group are reduced compared with those of the control group, and the difference has statistical significance (P < 0.05); after 35 days of HMB treatment, the rat body weight, wet weight, dry weight/body weight and cross-sectional area of the tibialis anterior muscle were all increased compared to the model group with statistical differences (P <0.05) (see table 1, table 2 and fig. 1 and fig. 2).
TABLE 1 comparison of rat body weight, tibialis anterior wet weight, dry weight/body weight for control, model and HMB-treated groups
The difference between the model group and the control group has statistical significance, and P is less than 0.05; indicates that the difference between the HMB treated group and the model group was statistically significant, P < 0.05.
TABLE 2 comparison of the Cross-sectional areas of tibialis anterior muscles of rats in the control, model and HMB-treated groups
The difference between the model group and the control group has statistical significance, and P is less than 0.05; indicates that the difference between the HMB treated group and the model group was statistically significant, P < 0.05.
Compared with the control group, the blood of the model group rats has obviously increased creatinine, urea nitrogen, uric acid and phosphorus, and the difference has obvious statistical significance (P <0.001), while the concentration of hemoglobin and calcium is obviously reduced compared with the control group, and the difference has obvious statistical significance (P <0.001) (see table 3).
TABLE 3 comparison of blood indices (M + -Q) of rats in control group and model group
#The difference between the model group and the control group has significant statistical significance, P<0.001。
The pathological section (HE staining) of the detected rat kidney shows that the number of glomeruli of the rat kidney in the control group is normal, no fibrosis and pathological changes of crescent moon and the like are seen (see figure 3B), the renal tubular morphology is normal, and no granuloma, inflammatory cell infiltration and fibrosis are seen in renal interstitium (see figure 3A); the glomerulus of the rat in the model group has no obvious pathological change, but renal tubule atrophy and cyst cavity expansion exist, crystals are deposited in the tubule cavity, a small amount of granular casts and protein casts are visible in part of the renal tubule cavity, foreign body granuloma formation, inflammatory cell infiltration and fibrous tissue hyperplasia are visible in renal interstitium (see figures 3C and 3D).
The pathological section (HE staining) of the gastrocnemius of the rat is detected to show that the gastrocnemius cells of the rat in the control group have normal morphology, no nuclear increase, no fibrous tissue hyperplasia and no lipofuscin (figure 4A); the rat gastrocnemius fibrous tissue of the model group is hyperplastic, the muscle fiber is thin and disorganized (see fig. 4B); the rats treated with HMB had improved gastrocnemius muscle fiber proliferation and collagen fiber content compared to the model group (see FIG. 4C).
In conclusion, the model of the chronic renal failure sarcopenia rats can be successfully made, and the HMB can improve the chronic renal failure sarcopenia.
Further detecting mRNA expression amounts of rat gastrocnemius autophagy key genes LC3B, Beclin1, ULK1, Atg5, Atg7, Atg13 and vps-34 and levels of key proteins LC3B and p62 thereof, and researching whether HMB improves chronic renal failure sarcopenia by regulating autophagy.
Compared with the control group, the model group rat autophagy genes LC3B, Beclin1, ULK1, Atg5, Atg7, Atg13 and vps-34 are obviously up-regulated, and the difference has significant statistical significance (P <0.001) (see Table 4 and figure 5); the expression of autophagy key protein LC3B is up-regulated, the expression of P62 is down-regulated, and the difference is statistically significant (P <0.05) (see Table 5 and FIG. 6). The expression of the autophagy-related genes and proteins was reversed after HMB intervention treatment, with statistical differences ((P <0.001, P <0.05) (see table 5 and fig. 6).
TABLE 4 gastrocnemius autophagy group in control group, model group and HMB-treated groupComparison by LC3B, Beclin1, UlK1, Atg5, Atg7, Atg13 and vps-34
#The difference between the model group and the control group has significant statistical significance, P<0.001；##Shows that the difference of the HMB treatment group and the model group has significant statistical significance, P<0.001。
Table 5: comparison of gastrocnemius autophagy genes p62 and LC3B in control group, model group and HMB-treated group
The difference between the model group and the control group has statistical significance, and P is less than 0.05; indicates that the difference between the HMB treated group and the model group was statistically significant, P < 0.05.
In summary, chronic renal insufficiency leads to complex pathophysiological changes, in which decreased protein synthesis and increased degradation lead to loss of muscle mass, and ultimately to sarcopenia. In recent years, a great deal of foreign research shows that HMB plays an important role in the intervention treatment of sarcopenia caused by various diseases, and the supplement of HMB can be used for improving the sarcopenia. However, the therapeutic efficacy and molecular mechanism of HMB in sarcopenia with chronic renal failure is not clear. Our study showed that in rats with chronic renal failure and sarcopenia, the weight, the wet weight, the dry weight/the weight and the cross-sectional area of the tibialis anterior muscle of the rats are increased compared with those of the model group, namely, the sarcopenia is improved. The autophagy-related genes in the gastrocnemius of the rat in the model group are obviously up-regulated, the expression of autophagy key protein LC3B is up-regulated, and the expression of p62 is down-regulated. After HMB treatment, the expression of the above genes and proteins was reversed in rats. It was thus confirmed that HMB can improve chronic renal failure sarcopenia, and it is to improve chronic renal failure sarcopenia by modulating autophagy.
The above-mentioned embodiments are only examples of the present invention, which is only used for illustrating the present invention, and not for limiting the present invention, and any changes and substitutions that do not go through the inventive step should be covered within the protection scope of the present invention, and the protection scope of the present invention should be subject to the scope defined by the claims.
Drawings
FIG. 1: body weight (g) change in control, model and HMB treated rats from week 1 to week 5: the weight of the model group is reduced compared with that of the control group, and the difference has statistical significance (P < 0.05); the difference in weight gain from day 14 in the HMB treated group compared to the model group was statistically significant (. about.p < 0.05);
FIG. 2: comparison of wet weight, dry weight/body weight, cross-sectional area of the tibialis anterior muscle of rats in control group, model group and HMB treated group: compared with the control group, the model group has reduced muscle mass and cross-sectional area of the tibialis anterior muscle, and the difference has statistical significance (P < 0.05); the HMB treatment group has the indexes increased compared with the model group, and the difference has statistical significance (P < 0.05);
fig. 3 (confirmation of successful modeling of rat model of chronic renal failure): rat kidney pathological sections (HE staining) of control, model and HMB treated groups; wherein, A: control rats normal renal tubules (X100); b: normal kidney tissue (X100) of control rats; c: model group rat renal tubular atrophy + crystallization + foreign body giant cell (X200); d: HMB-treated rat kidney crystals (X200);
FIG. 4: pathological sections of gastrocnemius muscles of rats in a control group, a model group and an HMB-treated group (HE staining); wherein, A: control group (X100); b: a model group (X100); c: HMB treatment group (X100);
FIG. 5: the expression level of autophagy-related gene mRNA in gastrocnemius muscles of rats in the control group, the model group and the HMB-treated group was changed: the expression of the mRNA of the autophagy related gene of the rat in the model group is obviously increased compared with that of the control group, and the difference has obvious statistical significance (#P<0.001); rat autophagy-related gene in HMB treatment groupThe mRNA expression is obviously reduced compared with the model group, and the difference has statistical significance (##P<0.001)。
FIG. 6: changes in expression of autophagy key proteins LC3B and p62 in gastrocnemius muscles of rats in control, model and HMB treated groups: compared with the control group, the model group rats have higher autophagy key protein LC3B, lower P62 and statistical significance in difference (P < 0.05); HMB treated rats the autophagy key protein was reversed compared to the model group, and the differences were statistically significant (. about.p < 0.05).
Claims (5)
1. A food with a formula for special medical purposes is characterized in that the effective component of the food is β -Hydroxy- β -Methylbutyrate (β -Hydroxy- β -methylbutryrate, HMB).
2. The food formulation for special medical use according to claim 1, characterized in that: the special medical food has a treatment effect on chronic renal failure sarcopenia.
3. The food formulation for special medical use according to claim 2, characterized in that: the food with the special medical purpose formula regulates the expression of autophagy-related genes and autophagy key proteins, and improves the sarcopenia caused by chronic renal failure.
4. The food formulation for special medical use according to claim 3, characterized in that: downregulating the expression of autophagy-related genes LC3B, Beclin1, ULK1, Atg5, Atg7, Atg13, and vps-34.
5. The food formulation for special medical use according to claim 3, characterized in that: reversing autophagy key proteins LC3B, p 62.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010129786.2A CN111227243A (en) | 2020-02-28 | 2020-02-28 | Food with special medical application formula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010129786.2A CN111227243A (en) | 2020-02-28 | 2020-02-28 | Food with special medical application formula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111227243A true CN111227243A (en) | 2020-06-05 |
Family
ID=70861961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010129786.2A Pending CN111227243A (en) | 2020-02-28 | 2020-02-28 | Food with special medical application formula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111227243A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104411305A (en) * | 2012-03-19 | 2015-03-11 | 雅培制药有限公司 | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance |
| CN107373673A (en) * | 2017-08-22 | 2017-11-24 | 河北健素临床营养有限公司 | Full nutrition formula food for the disability patient of disability caused by cardiovascular and cerebrovascular diseases half |
| CN109641135A (en) * | 2016-01-21 | 2019-04-16 | 代谢科技有限公司 | Beta-hydroxy-Beta-methyl butyric acid (HMB) is used to adjust the composition and method of autophagy and lipophagia |
-
2020
- 2020-02-28 CN CN202010129786.2A patent/CN111227243A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104411305A (en) * | 2012-03-19 | 2015-03-11 | 雅培制药有限公司 | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance |
| CN109641135A (en) * | 2016-01-21 | 2019-04-16 | 代谢科技有限公司 | Beta-hydroxy-Beta-methyl butyric acid (HMB) is used to adjust the composition and method of autophagy and lipophagia |
| CN107373673A (en) * | 2017-08-22 | 2017-11-24 | 河北健素临床营养有限公司 | Full nutrition formula food for the disability patient of disability caused by cardiovascular and cerebrovascular diseases half |
Non-Patent Citations (4)
| Title |
|---|
| 刘佳配等: "自噬-溶酶体系统与慢性肾衰竭营养不良", 《临床医学工程》 * |
| 刘佳配等: "自噬-溶酶体系统与慢性肾衰竭营养不良", 《临床医学工程》, no. 06, 15 June 2018 (2018-06-15), pages 835 - 836 * |
| 朴英实等: "《分子病理生物学实验技术指南》", 知识产权出版社, pages: 87 - 88 * |
| 邵枫等: "自噬在肾脏疾病发生中的作用", 《中华肾病研究电子杂志》, no. 05, 15 October 2014 (2014-10-15), pages 268 - 271 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4511031B2 (en) | Intra-articular injection composition and injectable aqueous composition preparation method | |
| CN1917866B (en) | Use of treprostinil, its derivant or pharmaceutically acceptable salt, in preparing medicine to treat and prevent ischemic lesions | |
| JPH07505378A (en) | Wound treatment treatment for fibrotic disorders | |
| JPH06504286A (en) | How to use Human IGF-I | |
| König et al. | Improved management of congestive heart failure: use of continuous ambulatory peritoneal dialysis | |
| US20100331746A1 (en) | Method of using enoxaparin for reducing the risk of death in acutely ill medical patients | |
| Somaschini et al. | Extracorporeal veno-venous ultrafiltration in patients with acute heart failure | |
| CN101032512B (en) | Medicine composition for expanding blood volume and the preparing method thereof | |
| CN111227243A (en) | Food with special medical application formula | |
| CN1806816A (en) | Pharmaceutical composition for treating bone diseases and method for preparing the same | |
| CN114588164B (en) | Application of Rui Malun in prevention of perioperative hypothermia and shivering | |
| Dees | The use of cortisone in interstitial cystitis: a preliminary report | |
| Schreiner et al. | The patient with chronic renal failure and surgery | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
| CN113956334A (en) | Application of brown adipocyte secretory peptide and derivative thereof in prevention and treatment of obesity | |
| CN115400139B (en) | Composition for pulmonary arterial hypertension and application thereof | |
| Lai et al. | Hemofiltration in digoxin overdose | |
| RU2305542C1 (en) | Anesthetic aid method in surgically treating scoliosis cases | |
| Yusupov et al. | Features of perioperative management of children with diffuse appendicular peritonitis. | |
| SU1069816A1 (en) | Method of treatment of non-specific ulcerative colitis | |
| CN116655773B (en) | Peptide hormone Elabela mutant and application thereof in heart and kidney syndrome | |
| RU2406539C2 (en) | Method of treating chronic renal insufficiency | |
| WO1999030698A1 (en) | A drug for treating diabetic nephrosis and delaying renal failure | |
| WO2019168063A1 (en) | Peritoneal dialysate fluid, peritoneal dialysate fluid set, composition for use in peritoneal dialysis, and peritoneal dialysis method | |
| RU2336898C2 (en) | Method of blood saving of patient at orthopedic surgical interventions with prognosticated significant or massive hemorrhage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200605 |